| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Twist Bioscience Corporation | Mar 30, 2022 | |
| Buy | TWIST BIOSCIENCE CORP CMN | Aug 23, 2021 | |
| Buy | TWIST BIOSCIENCE CORP. CMN | May 1, 2020 | |
| Buy | Twist bioscience Corporation | Mar 2, 2020 |
This page tracks congressional stock trading activity in Twist Bioscience Corporation (TWST) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving TWST. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of April 2022 — Disclosed Capitol has tracked 4 disclosed congressional trades in Twist Bioscience Corporation (TWST) — 3:1 buy-heavy ratio — led by Dwight Evans (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Mar 30, 2022 | Dwight Evans | D | Sell | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| May 1, 2020 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Mar 2, 2020 | Dwight Evans | D | Buy | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in Twist Bioscience Corporation (TWST), members of Congress have reported 3 buys and 1 sell. The average 30-day alpha vs. the S&P 500 is 23.42%.
As of October 2026, corporate insiders at Twist Bioscience Corporation have filed 99 SEC Form 4 transactions in TWST over the past 12 months — including 90 sells worth $126.1M.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $369K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $97K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $206K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $88K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $59K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $61K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $30K |
| 2026-10-05 | Leproust Emily M. — Chief Executive Officer | Sale | $9K |
| 2026-10-02 | Laponis Adam — Chief Financial Officer | Sale | $1.5M |
| 2026-10-02 | Green Paula — SVP of Human Resources | Sale | $1.9M |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
As of June 2026, Twist Bioscience Corporation has 20 federal contract award records on file from USAspending.gov — most recently $97K from the Department of Justice on 2026-06-29.
| Award date | Agency | Amount |
|---|---|---|
| 2026-06-29 | Department of Justice · Federal Bureau of Investigation | $97K |
| 2026-06-08 | Department of Defense · Department of the Navy | $50K |
| 2025-08-05 | Department of Agriculture · Agricultural Research Service | $61K |
| 2024-11-20 | Department of Health and Human Services · National Institutes of Health | -$1.8M |
| 2024-08-19 | Department of Veterans Affairs | $150K |
| 2024-08-19 | Department of Veterans Affairs | $105K |
| 2024-07-25 | Department of Health and Human Services · Centers for Disease Control and Prevention | $157K |
| 2024-05-25 | Department of Health and Human Services · Centers for Disease Control and Prevention | -$100K |
| 2023-08-25 | Department of Health and Human Services · Centers for Disease Control and Prevention | $51K |
| 2023-07-06 | Department of Health and Human Services · National Institutes of Health | $78K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Twist Bioscience Corporation reported revenue of $376.6M and net income of -$77.7M, per SEC filings.
Most recent reported quarter: Q3 FY2026 — revenue $118.4M, net income -$35.1M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.